ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2847

Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA

Paul Studenic1, David Felson 2, Maarten de Wit 3, Farideh Alasti 4, Tanja Stamm 1, Josef Smolen 1 and Daniel Aletaha 1, 1Medical University of Vienna, Vienna, Austria, 2Boston University School of Medicine, Department of Rheumatology, Boston, 3Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, 4Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Clinical research, patient-reported outcome measures, remission and outcome measures, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: 5T114: RA – Diagnosis, Manifestations, & Outcomes IV: Outcomes (2846–2851)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The patient global assessment (PGA) is a core set variable to assess RA disease activity. It is strongly linked to patient-reported pain and is a limiting factor for reaching when the ACR/EULAR Boolean remission definition is used, where PGA may not be greater than 1 on a 0-10 scale. Here we assessed different PGA criteria.

Methods: We used data from six RCTs testing the efficacy of TNF inhibitors vs MTX. Included were 3 trials of early RA: ASPIRE (infliximab), Go Before (golimumab), PREMIER (adalimumab); and 3 of established RA: ATTRACT (infliximab), DE019 (adalimumab) and Go Forward (golimumab). We increased the threshold for the 0-10 score for PGA gradually by 0.5 (Boolean1.5) up to 3 (Boolean3.0), and also omitted the criterion completely (BooleanX, i.e. requiring only CRP, SJC, TJC≤1). We assessed frequencies of remission by these definitions at 6 and 12 months and evaluated agreement with the Index based (SDAI) definition of remission (which does not include an inherent cut-off for PGA). Further the impact on functional and radiographic outcomes after 1 year were explored based on achievement of each of these remission definitions at 6 months.  Using recursive partitioning (CART) we attempted to determine a PGA cut-off that optimized agreement with SDAI remission.

Results: Data from 2600 trial patients, 1680 with early RA (mean disease duration: 1.5±2.96years) and 920 with established RA (mean disease duration: 9.7±8.44 years) were included. The proportion of patients achieving Boolean remission increased with higher thresholds for PGA from 12.4% to 19.7% in early RA and 5.9% to 12.3% in established RA at 6 month and 19.9% to 30.1% and 11.4% to 22.5% respectively at 1 year. Best agreement with SDAI remission occurred at a PGA cut-off of 1.5 and 2.0, while agreement decreased with PGA thresholds of ≥ 2.5 (Figure). Compared with Boolean (using 1.0), at Boolean2.0 the number of persons who were in remission per SDAI criteria increased from 74% to 85% of all SDAI remitters at 6 months. In early RA patients evaluating data at 6 months CART analyses showed that optimal agreement with SDAI remission occurred at a PGA threshold between 1.4 and 1.7cm.

Changing PGA thresholds at 6 months did not affect radiographic outcome with scores similar across different thresholds (mean ꙙsmTSS for Boolean, 1.5, 2.0, 2.5, 3.0 and BooleanX were: 0.35±5.4, 0.38±5.14, 0.41±5.1, 0.37±4.9, 0.34±4.9 and 0.27±4.7). However, for both early and late RA, the lower the PGA threshold, the lower the HAQ score. The proportion attaining HAQ≤0.5 was 90.2%, 87.9%, 85.2%, 81.1%, 80.7% and 73.1% for Boolean, 1.5, 2.0, 2.5, 3.0 and BooleanX respectively. Omitting PGA was associated with much worse functional outcomes.

Conclusion: Increasing the PGA cut-off to 1.5cm would provide highest consistency between Boolean with the Index based remission; the integer cut-off of 2.0cm performed similarly and would also allow the use of numerical rating scales. This new cut-off discounts the excessive stringency of the current PGA cut-off in the remission context, while maintaining similar functional and radiographic long-term outcomes.


Disclosure: P. Studenic, None; D. Felson, None; M. de Wit, Abbvie, 5, 8, BMS, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Janssen-Cilag, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8; F. Alasti, None; T. Stamm, Janssen, 8, MSD, 8, Novartis, 8, Roche, 2, 8; J. Smolen, AbbVie, 2, 5, 8, Abbvie, 2, 5, Amgen, 5, 8, AstraZeneca, 2, 5, 8, Astra-Zeneca, 5, Astro, 5, 8, BMS, 5, Celgene, 5, 8, Celltrion, 5, Celtrion, 5, 8, Chugai, 5, Eli Lilly and Company, 2, 5, Gilead, 5, GlaxoSmithKline, 5, 8, ILTOO, 5, 8, ILTOO Janssen, 5, Janssen, 2, 5, 8, Lilly, 2, 5, 8, Medimmune, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, Novartis- Sandoz, 5, Novartis-Sandoz, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 5, Roche, 2, 5, Roche;, 2, 5, 8, Samsung, 5, 8, Sanofi, 5, 8, Sanofi-Aventis, 5, UCB, 5, 8; D. Aletaha, AbbVie, 2, 5, 8, AbbVie, Janssen, Lilly, Novartis, Pfizer, and Roche, 5, AbbVie, Merck Sharp and Dohme, and Roche., 2, Amgen, 5, 8, Bristol-Myers Squibb, 8, Bristol-Myers Squibb, Celgene, Merck Sharp and Dohme, and UCB, 8, Celgene, 5, 8, Janssen, 5, Lilly, 5, 8, Medac, 5, 8, Merck, 5, 8, Merck Sharp and Dohme, 2, 8, Novartis, 2, 5, 8, Pfizer, 5, 8, Roche, 2, 5, 8, Sandoz, 5, 8, Sanofi/Genzyme, 5, 8, UCB, 8.

To cite this abstract in AMA style:

Studenic P, Felson D, de Wit M, Alasti F, Stamm T, Smolen J, Aletaha D. Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/testing-different-thresholds-for-patient-global-assessment-in-defining-acr-eular-boolean-remission-criteria-for-ra/. Accessed April 1, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/testing-different-thresholds-for-patient-global-assessment-in-defining-acr-eular-boolean-remission-criteria-for-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences